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Objectives This study tested whether immunosuppression with mycophenolate mofetil (MMF) inhibits atherosclerosis devel-
opment in apolipoprotein-E–deficient (Apoe/) mice and investigated the mechanism.
Background Chronic vascular inflammation involving both innate and adaptive immunity is central in the development of ath-
erosclerosis, but immunosuppressive treatment is not uniformly beneficial. The immunosuppressive MMF targets
lymphocyte proliferation by inhibiting inosine-monophosphate dehydrogenase.
Methods Young and aged Apoe/ mice were treated with 30 mg/kg daily MMF during 12 and 3 weeks of a high-fat diet,
respectively. Aortic lesion size and composition was investigated by histology and flow cytometry; soluble inflam-
matory mediators were investigated by enzyme-linked immunosorbent assay.
Results Macroscopic and histologic aortic atherosclerotic lesions were significantly decreased in both MMF-treated
groups. While systemic immunoglobulin G directed against low-density lipoproteins was not significantly altered,
the T-cell cytokine interleukin (IL)-17 was significantly reduced in plasma of MMF-treated mice and supernatants
from their aortas after T-cell stimulation. The MMF treatment decreased aortic  T-cell receptor lymphocyte
proliferation and cell numbers. Also, aortic contents of CD11bCD11c cells and their proliferation were re-
duced in MMF-treated Apoe/ mice. The IL-17 supplementation restored the number of proliferating aortic
CD11bCD11c cells in MMF-treated mice. The IL-17 receptor A was highly expressed on circulating monocytes
that are macrophage progenitors. Genetic deletion of IL-17 receptor A or IL-17A reduced inflammatory perito-
neal CD11bCD11c macrophage accumulation.
Conclusions The lymphocyte-directed immunosuppressant MMF that curbs IL-17 production was a successful antiatheroscle-
rotic treatment. Our data delineate a role for IL-17 in CD11bCD11c cell accumulation. (J Am Coll Cardiol
2011;57:2194–204) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.030t
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lInflammatory leukocyte immigration into the vessel wall,
proliferation, and differentiation is central during athero-
sclerotic plaque formation (1), the major cause of death
worldwide (2). While foam cell forming macrophages are
the most prominent cells, lymphocytes are present in the
atherosclerotic intima, media, and adventitia in humans (3)
and mice (4), and proliferate in human atherosclerotic
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2010, accepted December 15, 2010.arteries (5). Dissection of adaptive immune components in
genetic deletion models provides evidence that B cells
protect against atherosclerosis development by production
of antibodies directed against oxidized low-density lipopro-
tein (LDL) (6–8). The effect of T cells on atherosclerosis
formation depends on the T-cell subtype. The TH1 cells and
he TH1 marker interferon- promoted atherosclerotic dis-
ase in a large number of models, the role of TH2 cells is not
clear (9,10), and anti-inflammatory regulatory T cells and
their key signaling molecules limited atherosclerotic lesion
formation (11,12). The role of TH17 cells that produce
nterleukin (IL)-17 (also called IL-17A [13]) in atheroscle-
osis is currently under investigation. Transplantation of LDL-
eceptor deficient (Ldlr/) mice with IL-17 receptor A
IL-17ra) deficient (Il17ra/) bone marrow decreased
esion size (14) as did blockade of IL-17 receptor signaling
15) or IL-17A in apolipoprotein E (Apoe) deficient
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May 24, 2011:2194–204 Mycophenolate Decreases Atherosclerosis(Apoe/) mice (16), but IL-17 injection into Ldlr/ mice
decreased atherosclerotic lesion size according to another
report (17).
Pharmacologic intervention during atherosclerotic lesion
formation with systemic immunosuppression yielded diverse
and rarely beneficial effects. Cyclosporin A at a dose that
affected T-cell function, but not B cell function, enhanced
atherosclerotic lesion development in cholesterol-fed rabbits
(18). FTY720 reduced atherosclerosis in Apoe/ mice (19)
nd Ldlr/ mice (20) on a high-fat diet, but also increased
circulating lipid levels in Apoe/ mice on a chow diet (21).
ycophenolic acid (MPA) is a purine antagonist that acts
y inhibition of inosine-monophosphate dehydrogenase and
hereby blocks de novo generation of guanosine nucleotides
equired by proliferating cells, while other cells use a salvage
athway (22). MPA preferentially targets the inosine-
onophosphate dehydrogenase-II isoform that is mainly
xpressed in activated B and T lymphocytes (22,23). My-
ophenolic acid effects on vascular disease in transplanted
rgan allografts were favorable compared to those of calcineu-
in inhibitors, but also compared to 6-mercaptopurine, another
urine antagonist (24–26). Beneficial effects of MPA on
ative vessel atherosclerosis have been proposed (27,28) but
xperimental data are limited to 2 short reports describing
ecreased intimal thickness in rabbits that were given either
0 mg/kg of the pro-drug mycophenolate mofetil (MMF)
er gavage (29) or 80 mg/kg subcutaneously (30) during 12
eeks of a high-fat diet. No mechanism was investigated.
This study tested the impact of MMF, an immunosup-
ressant approved for use in humans that is comparatively
ell tolerated, on atherosclerotic lesion formation in
poe/ mice. We characterized the aortic leukocyte infil-
rate and cytokine production to determine mechanisms of
MF’s atheroprotective effects.
ethods
nimals. Wild-type C57Bl/6 mice, Apoe/ mice (Jackson
abs, Bar Harbor, Maine), mice lacking IL-17A (Il17a/
[Dr. Iwakura, Tokyo, Japan]), or IL-17-receptor-A
(Il17ra/ [Dr. Peschon, Amgen, Thousand Oaks, Cali-
fornia], both 96% C57Bl/6 background, males and females)
were genotyped by polymerase chain reaction and used in
age- and sex-matched groups. Animal numbers for each
specific analysis are given in the figure legends. Animal
experiments were approved by the Animal Care Committee
at La Jolla Institute for Allergy and Immunology.
Mycophenolate as the pro-drug MMF (Roche Pharma
AG, Grenzach-Wyhlen, Germany) was incorporated into a
high-fat diet without cholate (405 kcal from fat, 1.5%
cholesterol [Research Diets, New Brunswick, New Jersey])
to reach an oral dose of 30 mg/kg body weight daily at a chow
consumption of 0.1 g/g body weight. Monitored chow con-
sumption was 2.9  0.09 g (n  33 daily measurements at a
body weight of 21.7  1 g [n  8 mice]), resulting in an
average consumption of 0.13 g/g daily. Addition of 10%plasma from treated mice inhib-
ited T-cell proliferation to 59.9 
8% of control Apoe/ mice on a
high-fat diet plasma (n  6), rep-
resenting a plasma concentration
of 1.6 1.4 g/ml compared to a
standard curve, as described (31).
Blood for leukocyte counts was
analyzed by an automatic analyzer
(Hemavet 950FS, DREW Scien-
tific, Oxford, Connecticut). Total
plasma cholesterol was analyzed
using resorufin fluorescence ac-
cording to the manufacturer’s in-
structions (Cayman, Ann Arbor,
Michigan). Recombinant IL-17A
was from Peprotech (Rocky Hill, New Jersey).
Quantification of atherosclerosis and histologic analysis.
Aortas were excised, fixed, and stained with Sudan IV
(Sigma-Aldrich, St. Louis, Missouri) (counterstain fast
green/hematoxylin) (32). Digital images were obtained
using Moticam 1000 (Motic Instruments, Richmond, Brit-
ish Columbia, Canada) on an Olympus S267 dissection
scope (Olympus, Center Valley, Pennsylvania). Five-
millimeter sections of aortic roots starting at the aortic valve
plane and covering 300 m in 50-m intervals were used
for histologic lesion size quantification (photomicrographs
taken with a 4 objective/Nikon eclipse 80i microscope,
Sudan IV/hematoxylin/light-green stain). Lesion size was
determined using National Institutes of Health (NIH)
ImageJ software and averaged over all sections per mouse.
For immunofluorescence, purified rat-anti-CD3 (17A2,
eBioscience, San Diego, California) was used with goat
anti-rat-Alexa488 (Invitrogen, Carlsbad, California). Im-
ages were acquired on a Leica DM6000 upright microscope
with DIC optics using a HCX PLAPO 20 oil-immersion
objective at 488 nm excitation wavelength (Leica, Wetzlar,
Germany). The NIH Image J software was employed to
adjust brightness and for 1-step smoothing.
Enzymatic digestion of tissues and flow cytometry. After
sacrifice and perfusion (phosphate-buffered saline with 20
U/ml heparin), complete thoracic and abdominal aortas were
freed of all visible adventitial fat at 4 magnification and
digested as described (33). The T-cell stimulation was con-
ducted with plate-bound purified anti-CD28 and anti-CD3
(Biolegend, San Diego, California) in full RPMI medium.
Flow cytometry analysis was performed on a Becton Dickinson
LSR II (Franklin Lakes, New Jersey), and data were analyzed
using FlowJo software (Tree Star, Ashland, Oregon). For aorta
analysis, all events were acquired; 500,000 events were read for
all other organs. Gating was performed for live, CD45 events
constituting the total leukocyte population (leukocyte viability
35% to 60%). Antibody clone numbers are available from the
authors. Aqua LIVE/DEAD fixable dead cell stain kit (Invit-
rogen), BD-Fix-Perm (Becton Dickinson), and APC bro-
Abbreviations
and Acronyms
Apoe  apolipoprotein E
BrdU  bromodeoxyuridine
Ig  immunoglobulin
IL  interleukin
IL-17ra  interleukin-17
receptor A
LDL  low-density
lipoprotein
MMF  mycophenolate
mofetil
MPA  mycophenolic acid
TCR  T-cell receptormodeoxyuridine (BrdU) flow kit (BD Pharmingen, San Jose,
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Mycophenolate Decreases Atherosclerosis May 24, 2011:2194–204California) were used according to the manufacturer’s instruc-
tions. The gate for BrdU cells was set by cells from non-
rdU–injected animals after identical preparation and antibody
reatment.
hioglycolate-induced peritonitis. One milliliter BBL
uid thioglycolate medium (Becton Dickinson, Sparks,
aryland) was injected intraperitoneally, and cells were
ecovered after 3 days by washing twice with 5-ml
hosphate-buffered saline.
nzyme-linked immunosorbent assay. DuoSet enzyme-
inked immunosorbent assay development kit for IL-17A
R&D Systems, Minneapolis, Minnesota) and BD cyto-
etric beads array mouse Th1/Th2/Th17 cytokine kits (BD
iosciences, Sparks, Maryland) were used according to the
anufacturers’ instructions.
uantification of anti-native LDL, anti-malondialdehyde
DL, and anti-oxidized LDL antibody titers. Antibody
iters were determined by chemiluminescent enzyme-linked
mmunosorbent assay, as described (34).
tatistical analysis. Two-tailed Student t test or Wilcoxon
est was used to compare treated with untreated conditions
or normally and non-normally distributed parameters (if
ndicated by d’Agostino-Pearson test), respectively. One-
ay analysis of variance was used if 2 conditions were
ompared. p values0.05 were considered significant. Data
re expressed as mean SEM. (All p values are indicated as
 0.05 and p  0.01.)
esults
MF treatment is well tolerated and decreases aortic
esion size in Apoe/ mice. Apoe/ mice were main-
ained on a high-fat diet for 12 weeks. MMF at a typical
linical dose of 30 mg/kg daily was well tolerated, and no
iarrhea, a typical side effect, occurred. Although treated
ice gained slightly less weight than controls, plasma
holesterol levels were not significantly different (Table 1).
he MMF treatment decreased total lymphocyte counts in
pleen and peripheral blood (Table 1).
Atherosclerotic lesion size was determined by Sudan IV
tain of whole aortas and aortic roots after 12 weeks on a
igh-fat diet. MMF significantly decreased en face athero-
clerotic lesion size (Figs. 1A and 1B). Histology of the
Characteristics of Apoe/ Mice After 12 WeekTable 1 Characteristics of Apoe/ Mice A
Co
Body weight, g 27.6 1
Spleen weight, g 0.13 0
Plasma cholesterol, mg/dl 543 5
Lymphocytes/spleen 145 9
Peripheral blood lymphocytes, 103/ml 4.77 0
Peripheral blood monocytes, 103/ml 0.45 0
Values given as mean  SEM (n). The p value was calculated using S
Apoe  apolipoprotein E; MMF  mycophenolate mofetil.ortic roots also demonstrated a significant decrease inesion area (Figs. 1C and 1D). While the total lesion size
as decreased, the proportions of lipid or collagen staining
Sudan IV and Picrosirius red; data not shown) were not
ignificantly altered.
MF decreases inflammatory cytokine concentration in
lasma of atherosclerotic mice. To test the impact of
MF treatment on mediators of systemic adaptive immu-
ity, plasma antibody and cytokine concentrations were
tudied after 12 weeks of a high-fat diet. Total circulating
Figure 1 MMF Reduces Aortic Atherosclerotic Lesion Size
Seven-week-old apolipoprotein-E–deficient (Apoe/) mice were treated with a
high-fat diet for 12 weeks. (A, B) Aortic lesion size was assessed by Sudan IV
staining percent of aortic surface area (control [ctrl], n  5, and mycopheno-
late mofetil [MMF], n  7, from 2 independent experiments). (C) Aortic root
lesions (300 mm following the aortic valve in 50-mm intervals) were signifi-
cantly reduced by MMF (n  4). (D) Examples of aortic root lesions are shown
(Sudan IV/light green); *p  0.05 by Student t test.
a High-Fat Diet2 Weeks of a High-Fat Diet
MMF p Value
24.8 1.7 (14) 0.003*
) 0.11 0.01 (14) 0.47
603 61 (6) 0.16
6 (12) 121 6.5 · 106 (12) 0.05†
) 3.44 0.28 (10) 0.03†
) 0.32 0.03 (10) 0.06
t test. *p  0.05. †p  0.01.s offter 1
ntrol
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2 (6)
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May 24, 2011:2194–204 Mycophenolate Decreases Atherosclerosisimmunoglobulin (Ig) M and IgG2c levels were unchanged,
but IgG1 that is considered TH2 associated was mildly but
ignificantly lower (Fig. 2A). The IgG1 and IgG2c directed
gainst native LDL, oxidized LDL, and MDA-LDL were not
ignificantly decreased by MMF treatment (Figs. 2B to 2D).
he pro-inflammatory cytokine tumor necrosis factor- and
L-6 plasma concentrations were significantly lower in MMF-
reated mice (Fig. 2E). Among T-cell cytokines in plasma, the
H2 marker IL-4 was below detection limit in both groups
(data not shown). Interferon- as a TH1 marker was not
significantly reduced. Interleukin-17A as a marker of TH17
lineage was significantly reduced (Fig. 2E).
Aortic T-cell IL-17 production and leukocyte infiltration
in atherosclerosis is decreased by MMF treatment. To
address cytokine changes in the atherosclerotic vessel, we
examined culture supernatants of aortic explants. Single-cell
Figure 2 Plasma Ig and Cytokine Levels in Control and MMF-Tr
Plasma immunoglobulin (Ig) levels after 12 weeks of a high-fat diet (starting age 7
IgG2c were unchanged; IgG1 slightly decreased in MMF-treated mice. (B to D) No
lipoprotein (LDL). (E) Plasma cytokine levels were determined by cytometric beads
test. Apoe/  apolipoprotein-E–deficient; IFN  interferon; IL  interleukin; MD
tein; TNF  tumor necrosis factor; other abbreviations as in Figure 1.suspensions from whole aortas were subjected to 48-h T-cell
stimulation with anti-CD3 and anti-CD28. Subsequently,
T-helper subtype marker cytokine secretion into the super-
natant was analyzed. Figure 3A shows that aortic IL-17, but
not interferon- or IL-4, production was significantly de-
creased in aortas harvested from MMF-treated animals.
We examined the effects of oral MMF treatment on
aortic leukocytes in Apoe/ mice at 3 weeks on a high-fat
iet. At this time point, atherosclerotic lesions became
isible as fatty streaks, mainly in the innominate artery.
plenic and circulating lymphocyte counts were very similar
n MMF-treated and control mice (data not shown). Leu-
ocyte quantification was performed by flow cytometry.
igures 3B and 3C show a significant decrease in all
eukocytes and  T-cell receptor (TCR) cells in the
aortas of MMF-treated mice. We also tested whether MMF
d Apoe/ Mice
s) were assessed by enzyme-linked immunosorbent assay. (A) Total IgM and
cant changes were observed in IgG1 or IgG2c directed against either low-density
(n  10 per group from 3 independent experiments); *p  0.05 by Student t
alondialdehyde; MPA  mycophenolic acid; oxLDL  oxidized low-density lipopro-eate
week
signifi
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Mycophenolate Decreases Atherosclerosis May 24, 2011:2194–204treatment was effective in aged mice with pre-existing disease.
Twenty-week-old to 22-week-old Apoe/ mice were given a
igh-fat diet with or without MMF for 3 weeks. Again, T-cell
nfiltration into the aorta quantified by flow cytometry was
ignificantly smaller in the MMF treatment group (Fig. 4A).
oth macroscopic aortic arch (Fig. 4B) and histologic lesions
Figs. 4C and 4D) were smaller in MMF-treated mice.
MF treatment decreases the number of proliferating
lymphocytes in the aorta during development of
therosclerosis. Treatment with MMF inhibits lympho-
yte proliferation. Aortic leukocyte proliferation is highest
arly in atherosclerosis development (35). Cell proliferation
as assessed 24 h after intraperitoneal BrdU injection after
weeks of a high-fat diet with and without MMF (Fig. 5).
roliferation in TCR cells recovered from the aorta was
markedly higher than in spleen, where 1% of TCR
cells proliferated within 24 h (Figs. 5A and 5B). The low
level of proliferation in spleen was not significantly altered
by MMF at 30 mg/kg as employed in our trial. The amount
of  TCR cells in the aorta that proliferated was
Figure 3 MMF Treatment Reduces Aortic IL-17 Production and
T cells from aortas of apolipoprotein-E–deficient (Apoe/) mice after 3 weeks of
were stimulated with anti-CD3 and anti-CD28 for 48 h. (A) Cytokines in the supern
6). (B) Aortic leukocytes were assessed by flow cytometry. (C) Total cell counts a
n  8, and MMF, n  10, from 3 independent experiments); *p  0.05 by Studesignificantly decreased by MMF (Figs. 5C and 5D). nFewer aortic T cells in MMF-treated mice with established
atherosclerosis after 12 weeks of a high-fat diet. Leukocytes
from aortas of mice with established atherosclerosis after 12
weeks of a high-fat diet were analyzed. Similar to the early
time point, both the percentage among all leukocytes and
the absolute number of infiltrating TCR cells were
ignificantly decreased by MMF (Figs. 6A and 6B). The
roportions of CD4CD25 cells, which include regula-
tory T cells, in aorta and spleen were unaltered (data not
shown), arguing against a major impact of MMF on this cell
type in this model. Immunofluorescence was used for
localization of T cells within the aortic wall. The CD3 T
cells were found in clusters in the adventitia, and also in the
plaque. In aortas of MMF-treated mice, the CD3 T-cell
umbers were decreased and adventitial clusters dispersed
Fig. 6C).
MF treatment alters aortic macrophages indirectly via
epression of IL-17. We further investigated aortic mac-
ophages, which are central in atherosclerosis development.
lthough MMF did not significantly decrease the total
ll Accumulation in Aorta
-fat diet with and without mycophenolate mofetil (MMF [starting age, 7 weeks])
were analyzed by cytometric bead assay (control [ctrl], n  5, and MMF, n 
T-cell receptor (TCR) cells were significantly reduced by MMF treatment (control,
t. IFN  interferon; IL  interleukin.T-Ce
a high
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nd 
nt t tesumber of CD11b macrophages, approximately one-half
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May 24, 2011:2194–204 Mycophenolate Decreases Atherosclerosisof aortic CD11bCD45 leukocytes also expressed the b2
ntegrin subunit CD11c after 12 weeks of a high-fat diet in
ontrol Apoe/ mice. In MMF-treated animals, there were
ewer CD11bCD11c than CD11bCD11c cells among
all CD11b cells (Fig. 7A). The mean fluorescence inten-
ity reflecting the number of CD11b and CD11c molecules
n the surface of each individual cell in the aortic
D11bCD11c population remained unaffected by
MF treatment (data not shown), suggesting that the
bserved effect was a decrease in a cell population rather
han relative integrin surface expression. The CD11c is
xpressed on CD11b cells in atherosclerotic plaques and
p-regulated by oxidized LDL (35,36). A CD11c deficiency
ecreased atherosclerotic lesion size (37). We assessed
roliferation of aortic CD11bCD11c cells after 3 weeks
of a high-fat diet. It was significantly decreased by treatment
with MMF (Fig. 7B).
To test whether the decreased proportion of CD11bCD11c
macrophages in MMF-treated mice aortas was a direct or a
Figure 4 MMF Reduces Atherosclerotic Lesion Size and Aortic
Twenty- to 22-week-old apolipoprotein-E–deficient (Apoe/) mice were given 3 we
etry analysis was performed for quantification of aortic  T-cell receptor (TCR) c
than in control mice (typical examples). (C) Histologic assessment of aortic roots
sis (control [ctrl], n  4, and MMF, n  5, from 2 independent experiments); *p downstream effect due to decreased IL-17 production,Apoe/mice were injected with either recombinant IL-17
or phosphate-buffered saline control on days 5, 10, and 15
of a 3-week course of a high-fat diet and MMF. That
completely restored CD11bCD11c proliferation in the
orta (Fig. 7C). At this point, atherosclerotic lesions were
inimal in the aortic root (data not shown), but macro-
copically visible in the branching innominate artery. These
ere reduced in MMF-treated mice, and this was reverted
y IL-17 treatment (Fig. 7D). Indeed, IL-17ra was highly
xpressed on circulating CD11bCD115 monocytes
Fig. 7E) that are precursors of aortic macrophages (35,36).
o address whether IL-17 had a role in inflammatory
acrophage accumulation in circumstances other than MMF
reatment, we employed IL-17A (Il17a/)-deficient mice and
l17ra/ mice. Baseline circulating monocyte counts were
not significantly different from wild-type mice (data not
shown). Thioglycolate-induced peritoneal macrophages were har-
vested after 3 days. Fewer CD11bCD11c cells were recov-
red from the peritoneal cavity of both Il17ra/ and
ll Infiltration in Aged Apoe/ Mice
a high-fat diet with and without mycophenolate mofetil (MMF). (A) Flow cytom-
) Macroscopic aortic arch lesion size (arrows) was smaller in MMF-treated mice
ed a significantly decreased lesion size (typical examples). (D) Statistical analy-
by Student t test.T-Ce
eks of
ells. (B
reveal
0.05Il17a/ mice than from wild-type controls (Fig. 7F).
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Targeting lymphocyte proliferation by inhibition of inosine-
monophosphate dehydrogenase by MMF reduced athero-
Figure 5 MMF Treatment Reduces Aortic Lymphocyte Prolifera
After 3 weeks of a high-fat diet (starting age, 7 weeks) with and without mycophen
modeoxyuridine (BrdU) 24 h before sacrifice. The BrdU incorporation was detected
(C, D) aorta. Gates were set by identically prepared cells from the same organ of
treatment (control [ctrl], n  8, and MMF, n  10, from 3 independent experimensclerotic lesion formation in Apoe/ mice. This was Mchieved both during 12 weeks of a high-fat diet in young or
uring 3 weeks in aged mice.
MF effects on B cells and T cells and T-cell cytokine
roduction during development of atherosclerosis. The
During Development of Atherosclerosis
mofetil (MMF), apolipoprotein-E–deficient (Apoe/) mice were injected with bro-
bsequent intracellular staining of single cell suspensions from (A, B) spleen and
ot given BrdU. (D) Aortic T-cell proliferation was significantly decreased by MMF
 0.05 by Student t test. TCR  T-cell receptor.tion
olate
by su
mice n
ts); *pMF targets proliferating lymphocytes (22). We observed
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May 24, 2011:2194–204 Mycophenolate Decreases Atherosclerosisno significant change in IgG, which is considered to
mediate atheroprotection by B cells (6–8). Concerning T
lymphocytes, MMF treatment predominantly reduced aor-
tic TCR cell accumulation. The T-cell numbers were
educed in both plaque and adventitia. The proportion of
roliferating T cells was much higher in aortas with nascent
therosclerotic lesions than in the spleen of the same animal.
ortic T-cell proliferation was preferentially affected by
MF. Subsequently, after both 3 and 12 weeks of a
igh-fat diet, MMF treatment had a stronger effect on
Figure 6 Decrease in Aortic T Cells Is Sustained in Apoe/ M
Flow cytometry was used for quantification of leukocyte infiltration after 12 weeks
(TCR) T cells among all leukocytes (typical example), and (B) the absolute numb
(MMF [n  8 from 3 independent experiments); *p  0.05 by Wilcoxon test. (C) I
revealed decreased CD3-staining in the lesions of MMF-treated mice as compared
secondary (goat anti-rat-Alexa488) antibody served as specificity controls). Apoe/ortic lymphocyte populations than in spleen or peripheral Mlood. A very recent report suggests that similar effects can
e observed in humans: T lymphocytes in carotid endarter-
ctomy specimens from patients treated with MMF for 2
eeks before surgery were decreased (38).
Certain T-cell populations, especially TH1 and possibly
TH17 cells, have a pro-atherogenic role (1,11,39). Inhibition
f T-cell proliferation during an inflammatory event such as
therosclerotic lesion formation can reduce T-cell cytokines
y decreasing the number of cytokine producers. Indeed,
ystemic and aortic IL-17 cytokine levels were lower in
fter 12 Weeks of a High-Fat Diet With MMF
igh-fat diet (starting age 7 weeks). (A) The proportion of  T-cell receptor
TCR T cells per aorta were significantly reduced by mycophenolate mofetil
ofluorescence of frozen aortic root sections after 12 weeks of a high-fat diet
ontrol mice (original magnification, 20; bars represent 100 m; isotype and
polipoprotein-E–deficient.ice A
of a h
er of 
mmun
with c
  aMF-treated mice than in control mice. Our present
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Mycophenolate Decreases Atherosclerosis May 24, 2011:2194–204Figure 7 MMF-Mediated Decrease of Aortic CD11b
CD11c Macrophage Proliferation Is Rescued by IL-17,
and IL-17 Promotes CD11bCD11c Cell Accumulation In Vivo
(A) After 12 weeks of a high-fat diet, CD11c among CD11b leukocytes were reduced in aortas of mycophenolate mofetil (MMF)-treated mice compared with control
apolipoprotein-E–deficient (Apoe/) mice. (B) Aortic CD11bCD11c cell proliferation measured by bromodeoxyuridine (BrdU) incorporation was reduced after 3 weeks
of a high-fat diet (control, n  8, and MMF, n  10, from 3 independent experiments, starting age 7 weeks); *p  0.05 by Student t test. To test whether the decrease
in CD11bCD11c cell proliferation was due to inhibition of interleukin (IL)-17 production by MMF, recombinant IL-17 (1 mg/mouse) or phosphate-buffered saline (PBS)
control was injected intraperitoneally on days 5, 10, and 15 of a high-fat diet with MMF. (C) Aortic CD11bCD11c cell proliferation is depicted (control, n  9, and
MMF, n  10, from 2 independent experiments, starting age 7 weeks); *p  0.05 by Student t test. (D) Innominate artery lesions (arrows) at 3 weeks of Western diet
were reduced by MMF but restored in IL-17–substituted MMF-treated Apoe/ mice (typical examples). (E) Interleukin-17–receptor expression on peripheral blood
CD11bCD115 monocytes was analyzed by flow cytometry; monocytes from a Il17ra/ mice served as control. Peritoneal macrophages from wild-type (wt) mice,
Il17a/ mice, and Il17ra/ mice were harvested on day 3 after thioglycolate injection. Gray area indicates Il17ra/; black area indicates wild type. (F) The number
of CD11bCD11c macrophages per peritoneal cavity was lower in Il17a/ mice and Il17ra/ mice than in wild-type mice (n  4, from independent experiments,
Dunnett’s test after 1-way analysis of variance); *p  0.05; **p  0.01. Apoe  apolipoprotein E; IL-17ra  interleukin-17 receptor A.
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were preferentially affected by MMF treatment. However,
from the mechanism of action of MMF, it is conceivable
that these cells were most affected because they or their
progenitors were proliferating most actively, making them
most vulnerable to guanosine nucleotide depletion, similar
to the setting of bone marrow regeneration, as we recently
explored (31).
The role of IL-17 in atherosclerosis development. Most,
although not all, current literature suggests a pro-
atherogenic role of IL-17 (14–17,40) by a yet undefined
mechanism. Our data do not exclude that additional MMF
effects beyond IL-17 suppression have contributed to its
beneficial effects. However, we investigated whether IL-17
was involved in the effects of MMF-mediated T-cell sup-
pression on atherosclerosis by substituting IL-17 into
MMF-treated mice. This reverted the MMF effect on
nascent lesion formation and on a cellular level on aortic
CD11bCD11c macrophages. These cells are expanded
in atherosclerosis (35,36), present antigens to CD4 T cells,
and phagocytose lipids (39,40). The IL-17 receptor was
highly expressed on circulating monocytes that are progen-
itors of aortic macrophages. We tested for a direct link
between IL-17 and CD11bCD11c cells in acute perito-
eal inflammation in mice lacking IL-17A or IL-17ra. The
umber of CD11bCD11c cells was reduced in both
enotypes. Our data suggest IL-17 as a mediator of
D11bCD11c cell accumulation. Also, aortic CD11c
number was lower in Il17ra/ mice on a high-fat diet
ompared with wild-type controls (unpublished observa-
ion), suggesting relevance in vascular inflammation. The
L-17 increased monocyte adhesion to the atherosclerotic
ortic wall ex vivo (15), but it remains to be determined at
hich step IL-17 promotes CD11bCD11c cells. The
MMF-induced decrease in CD11bCD11c cells may
have contributed to systemically lower tumor necrosis
factor- and IL-6 inflammatory cytokine levels (Fig. 2) and
decreased numbers of neutrophils in early atherosclerotic
aortas (data not shown). The IL-6 can again induce T-cell
IL-17 production (41), a pro-inflammatory loop that was
tempered in MMF-treated mice.
Immunosuppression in atherosclerosis management.
Systemic inhibition of T-cell immunity in native vessel
atherosclerosis with other agents was pro-atherogenic for
cyclosporine (18) or only partially successful for FTY720
(19–21). Our finding that MMF conferred protection not
only to young mice, but also to aged mice is promising.
Further studies are necessary to delineate whether, in
addition to inhibiting new plaque formation, MMF also
decreased pre-existing disease in aged mice. Systemic im-
munosuppression with any of the currently available agents,
including MMF, despite a relatively favorable side effects
profile (22,42), confers major risks to patients. These
preclude their chronic use for atherosclerosis as the sole
indication; however, beneficial vascular side effects might
influence the choice of immunosuppressant prescribed forother conditions in patients with high cardiovascular risk.
Also, our finding that the alteration in CD11bCD11c
cells in aortas of MMF-treated atherosclerotic mice de-
pended on IL-17 suggests IL-17 as a mediator, and possibly
a more specific target, for immunosuppressive therapy of
atherosclerosis.
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